What is Wedbush’s Estimate for ORKA FY2029 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a research note issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($4.14) per share for the year. Wedbush has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share.

Several other research firms have also issued reports on ORKA. Wolfe Research started coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Trading Up 6.3%

Oruka Therapeutics stock opened at $10.06 on Friday. The firm has a market capitalization of $376.66 million, a P/E ratio of -1.61 and a beta of 0.25. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13. The business has a 50-day moving average of $9.86 and a 200-day moving average of $14.87.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ORKA. JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $144,000. AlphaQuest LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $168,000. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $195,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.